| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/25/2011 | US20110206742 Immunotherapeutic compositions for the treatment of alzheimer's disease |
| 08/25/2011 | US20110206721 Fermented soy nutritional supplements including mushroom components |
| 08/25/2011 | US20110206706 Vaccine and method for treatment of neurodegenerative diseases |
| 08/25/2011 | US20110206686 Il-23 antibodies |
| 08/25/2011 | US20110206684 Method of producing nutritional products from human milk tissue and compositions thereof |
| 08/25/2011 | US20110206682 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 08/25/2011 | US20110206679 New Therapeutic and Diagnostic Methods for Alzheimer's Disease |
| 08/25/2011 | US20110206675 Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases |
| 08/25/2011 | US20110206671 Axon regeneration promoter |
| 08/25/2011 | US20110206670 Methods and materials related to anti-amyloid antibodies |
| 08/25/2011 | US20110206669 Mcp1 fusions |
| 08/25/2011 | US20110206668 Methods and compositions for modulating immunity |
| 08/25/2011 | US20110206653 Tetrazole compounds for reducing uric acid |
| 08/25/2011 | US20110206652 Methods for treating atherosclerosis |
| 08/25/2011 | US20110206649 Nutritional composition comprising probiotics and improving sleep patterns |
| 08/25/2011 | US20110206648 Gene-enhanced tissue engineering |
| 08/25/2011 | US20110206644 Methods for trans-differentiating cells |
| 08/25/2011 | US20110206621 Oral transmucosal nicotine dosage form |
| 08/25/2011 | US20110206616 Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
| 08/25/2011 | US20110206610 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 08/25/2011 | US20110206607 Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| 08/25/2011 | DE102011009719A1 Agent useful e.g. for treating neurodermitis and diabetes mellitus comprises a fat phase including tocotrienols with lipids e.g. gamma -linolenic acid and an aqueous phase comprising e.g. palm fruit water, vitamin C, vitamin B2 and |
| 08/25/2011 | DE102010008981A1 Siliciumhaltiges, biologisch degradierbares Material zur pro-angiogenetischen Therapie A silicon-containing biologically degradable material for pro-angiogenic therapy |
| 08/25/2011 | CA2790330A1 Methods and compositions for use in aquaculture |
| 08/25/2011 | CA2790176A1 Triazolo [4, 5 - b] pyridin derivatives |
| 08/25/2011 | CA2789884A1 Solid forms comprising a cyclopropyl amide derivative |
| 08/25/2011 | CA2789058A1 Piperidine derivatives |
| 08/25/2011 | CA2788783A1 Heterocycles as potassium channel modulators |
| 08/25/2011 | CA2788656A1 (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
| 08/25/2011 | CA2788444A1 New crystalline form of a cyclopropyl benzamide derivative |
| 08/24/2011 | EP2360258A2 Aprotinin polypeptides for transporting a compound across the blood-brain barrier |
| 08/24/2011 | EP2360254A1 Assays for screening anti-pd-1 antibodies and uses thereof |
| 08/24/2011 | EP2360251A2 In vivo production of small interfering RNAs that mediate gene silencing |
| 08/24/2011 | EP2360185A2 Administration of agents for the treatment of inflammation |
| 08/24/2011 | EP2360184A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/24/2011 | EP2360155A1 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity |
| 08/24/2011 | EP2360142A1 N-substituted benzene sulfonamides |
| 08/24/2011 | EP2359855A2 Methods of administering anti-TNFalpha antibodies |
| 08/24/2011 | EP2359847A1 Modulation of beta-amyloid levels by beta-secretase bace2 |
| 08/24/2011 | EP2359842A1 Netrin-related compositions and uses |
| 08/24/2011 | EP2359832A2 Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof |
| 08/24/2011 | EP2359820A1 Shunt delivery of curcumin for the treatment Alzneimer |
| 08/24/2011 | EP2359819A1 Substituted styryl benzylsulfones for treating proliferative disorders |
| 08/24/2011 | EP2358723A1 Organic compounds |
| 08/24/2011 | EP2358719A1 Novel pyrroiol2,l-cu1.41benzodiazepine derivatives with dithiocarbamate side chains and process for the preparation thereof |
| 08/24/2011 | EP2358714A1 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes |
| 08/24/2011 | EP2358713A1 Imidazopyridazine derivatives acting as orexin antagonists |
| 08/24/2011 | EP2358712A1 Piperidine derivatives useful as orexin receptor antagonists |
| 08/24/2011 | EP2358711A1 Piperidine derivatives useful as orexin receptor antagonists |
| 08/24/2011 | EP2358707A2 Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders |
| 08/24/2011 | EP2358705A1 (r) -3- (e) -2- (pyrr0lidin-3-yl) vinyl) -5- (tetrahydr0pyran-4-yl0xy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors |
| 08/24/2011 | EP2358704A1 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase |
| 08/24/2011 | EP2358701A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 08/24/2011 | EP2358686A1 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| 08/24/2011 | EP2358681A1 Substituted 4-(1,2,3,4-tetrahydroisochinolin-2-yl)-4-oxo-butyric acid amide as kcnq2/2 modulators |
| 08/24/2011 | EP2358676A1 Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound |
| 08/24/2011 | EP2358675A1 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
| 08/24/2011 | EP2358376A1 Early treatment and prevention of increased muscle tonicity |
| 08/24/2011 | EP2358370A2 Treatment of proteinopathies using a farnesyl transferase inhibitor |
| 08/24/2011 | EP2358365A1 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives |
| 08/24/2011 | EP2358364A1 Therapeutics for neurological disorders |
| 08/24/2011 | EP2358204A1 Organic compounds |
| 08/24/2011 | EP1951687B1 N-hydroxyamide derivatives and use thereof |
| 08/24/2011 | EP1940818B1 Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase n inhibitors |
| 08/24/2011 | EP1878793B1 Novel protein and preventive/remedy for neurodegenerative disease such as polyglutamine disease using the same |
| 08/24/2011 | EP1846011B1 Composition comprising the extract of crude drug complex having neuroprotective activity for preventing and treating stroke |
| 08/24/2011 | EP1836164B1 11c-labeled benzyl-lactam compounds and their use as imaging agents |
| 08/24/2011 | EP1827409B1 Rasagiline orally disintegrating compositions |
| 08/24/2011 | EP1571155B1 Peptides and medicinal compositions containing the same |
| 08/24/2011 | EP1499729B1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 08/24/2011 | EP1490338B1 Use of an alfa2-adrenoreceptor antagonist for cns-related diseases |
| 08/24/2011 | EP1485353B1 New inhibitors of histone deacetylase |
| 08/24/2011 | EP1423404B1 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 08/24/2011 | EP1333833B1 Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases |
| 08/24/2011 | EP1025121B1 Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor |
| 08/24/2011 | EP1023067B2 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 08/24/2011 | CN1929816B Pharmaceutical compositions comprising midazolam in a high concentration |
| 08/24/2011 | CN1926114B Processes for preparing substituted N-aryl-N'-[3-(1H-pyrazol-5-yl) phenyl] ureas and intermediates thereof |
| 08/24/2011 | CN102165061A Modulation of TOLL-like receptor 9 expression by antisense oligonucleotides |
| 08/24/2011 | CN102164942A Triterpenoid compounds and methods of use thereof |
| 08/24/2011 | CN102164941A Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
| 08/24/2011 | CN102164927A Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine D3 receptors |
| 08/24/2011 | CN102164920A Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof as FAAH enzyme inhibitor |
| 08/24/2011 | CN102164917A Compounds which selectively modulate the CB2 receptor |
| 08/24/2011 | CN102164916A Compounds which selectively modulate the CB2 receptor |
| 08/24/2011 | CN102164914A Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors |
| 08/24/2011 | CN102164910A Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-CARBOXAMIDINE derivatives having CB1-antagonistic activity |
| 08/24/2011 | CN102164902A 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 08/24/2011 | CN102164886A Process for the preparation of O-desmethylvenlafaxine |
| 08/24/2011 | CN102164884A Hydroxybutyrate ester and medical use thereof |
| 08/24/2011 | CN102164606A Light-stabilized pharmaceutical composition |
| 08/24/2011 | CN102164594A Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs |
| 08/24/2011 | CN102161963A Grass root wine and preparation method thereof |
| 08/24/2011 | CN102161658A N-(naphthoxyalkyl)heteroarylpiperidine compounds and preparation method and applications thereof |
| 08/24/2011 | CN102161656A Caspase inhibitors and uses thereof |
| 08/24/2011 | CN102161644A Ligands for g-protein coupled receptors |
| 08/24/2011 | CN102161627A Omega-(N-substituted-aminoalkyl)octanamide |
| 08/24/2011 | CN102160894A Benzamide analog mediated brain-targeting delivery system |
| 08/24/2011 | CN102160890A Pharmaceutical composition comprising an analgesic peptide |
| 08/24/2011 | CN102160873A Method for preparing total polygala xanthone |